“…Currently, most efforts are focused on antibodies, organic molecules, or already approved drugs for other diseases, such as chloroquine, favipiravir, remdesivir, molnupiravir, nirmatrevir, paxlovid ( Akhtar, 2020 ), or the M pro inhibitor in phase 3 trial, S-217622 (ensitrelvir) ( Sasaki et al, 2022 ). As an alternative, metal-based compounds have also been explored as anti-SARS-CoV-2 agents ( Cirri et al, 2021 ; Gil-Moles et al, 2021 ; Karges and Cohen, 2021 ; Vlasiou and Pafti, 2021 ; Li et al, 2022 ; Ni et al, 2022 ).…”